11.66

1.13% 0.13

After Hours: 11.70 0.04 +0.34%

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $11.66, with a volume of 2.51M. It is up +1.13% in the last 24 hours and up +2.46% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$11.53

Open:

$11.5

24h Volume:

2.51M

Relative Volume:

0.43

Market Cap:

$8.62B

Revenue:

$158.30M

Net Income/Loss:

$4.74B

P/E Ratio:

-8.7015

EPS:

-1.34

Net Cash Flow:

$-710.11M

1W Performance:

+0.69%

1M Performance:

+2.46%

6M Performance:

+2.37%

1Y Performance:

+25.65%

1-Day Range:

$11.40

$11.67

1-Week Range:

$11.40

$11.83

52-Week Range:

$8.465

$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

441-295-5950

Address

CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11

Employee

908

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ROIV's Discussions on Twitter

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

05:08 AM

Vanguard Group Inc's Strategic Acquisition in Roivant Sciences L - GuruFocus.com

05:08 AM

01:05 AM

Roivant Sciences (ROIV) Scheduled to Post Earnings on Tuesday - MarketBeat

01:05 AM

06:53 AM

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by Impax Asset Management Group plc - MarketBeat

06:53 AM

Nov 04, 2024

Allspring Global Investments Holdings LLC Sells 115,694 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Nov 04, 2024

Oct 29, 2024

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - Yahoo Finance

Oct 29, 2024

Organon Completes Acquisition of Dermavant - njbmagazine.com

Oct 29, 2024

China Universal Asset Management Co. Ltd. Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Oct 29, 2024

Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 28, 2024

Organon completes Dermavant Sciences acquisition - Investing.com

Oct 28, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan

Oct 28, 2024

Oct 23, 2024

At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K - Benzinga

Oct 23, 2024

Options Exercise: Eric Venker At Roivant Sciences Realizes $782K - Benzinga

Oct 23, 2024

Oct 22, 2024

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares - MarketBeat

Oct 22, 2024

Roivant Sciences president sells $1.17 million in shares By Investing.com - Investing.com Australia

Oct 22, 2024

Roivant Sciences president sells $1.17 million in shares - Investing.com

Oct 22, 2024

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility (ROIV) - Seeking Alpha

Oct 22, 2024

Leerink maintains outperform on Roivant with steady target By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 20, 2024

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 20, 2024

Oct 17, 2024

Roivant Sciences (ROIV): High-Growth UK Stock with Innovative Drug Development Model - Insider Monkey

Oct 17, 2024

Oct 15, 2024

Exchange Traded Concepts LLC Makes New $2.27 Million Investment in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Oct 15, 2024

Oct 14, 2024